文献速递心境障碍

促肾上腺皮质激素释放激素结合蛋白基因变异预测抗抑郁药疗效

Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
PubMed 文献 · Am J Psychiatry · 2017-12-15

研究在iSPOT-D试验的636例患者中检验HPA轴16个候选SNP与三种抗抑郁药8周疗效的关系,发现CRHBP基因rs28365143变异预测缓解、应答和症状改善,且效果限于SSRI类药物,并在PReDICT样本中验证。

要点

  • CRHBP基因rs28365143的GG基因型与更高的缓解率、应答率和症状减分相关。
  • 该变异预测SSRI(艾司西酞普兰、舍曲林)疗效,但不预测SNRI(文拉法辛)疗效。
  • 按种族分层后基因型对治疗应答的总体效应仍然存在,验证样本中GG基因型同样与良好结局相关。

核心结论

  • CRHBP基因rs28365143变异可能有助于预测哪些患者对抗抑郁药改善更好以及哪种抗抑郁药可能最有效。

研究设计与样本

  • 测试样本为iSPOT-D研究中636例完成基线和8周随访且有完整基因分型数据的患者。
  • 采用多变量线性和逻辑回归检验16个候选HPA轴SNP与三种抗抑郁药疗效的关系,并作Bonferroni校正。
  • findings在PReDICT研究(未经治疗的重性抑郁患者结局预测研究)中验证。

主要发现

  • rs28365143位于CRHBP基因内,预测抗抑郁治疗的缓解、应答和症状变化。
  • rs28365143的G等位基因纯合子患者缓解率、应答率和症状减分均更高。
  • GG基因型患者对SSRI艾司西酞普兰和舍曲林的应答显著优于A等位基因携带者。
  • rs28365143基因型与SNRI文拉法辛的治疗结局无关。
  • 按种族分层后基因型对治疗应答的总体效应仍存在;验证样本中GG基因型再次与良好抗抑郁结局相关,效应量可比。

关键数值与推荐

  • 疗效定义:应答和缓解采用汉密尔顿抑郁量表定义。
  • 遗传标记:HPA轴16个候选单核苷酸多态性(SNP),重点为CRHBP基因rs28365143。
  • 药物:艾司西酞普兰、舍曲林(SSRI)和文拉法辛缓释剂(SNRI)。
  • 统计校正:Bonferroni校正。

临床怎么用

  • rs28365143 GG基因型可能提示对SSRI(艾司西酞普兰、舍曲林)的应答和缓解更优。
  • 该变异未见预测文拉法辛疗效,或可辅助区分SSRI与SNRI的个体化选择。

局限性

  • 测试样本为完成随访且有完整基因分型数据的患者,可能存在选择偏倚。
  • 验证样本为未经治疗的重性抑郁患者,研究结论需进一步在更广泛人群中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Genetic variation within the hypothalamic-pituitary-adrenal (HPA) axis has been linked to risk for depression and antidepressant response. However, these associations have yet to produce clinical gains that inform treatment decisions. The authors investigated whether variation within HPA axis genes predicts antidepressant outcomes within two large clinical trials. METHOD: The test sample comprised 636 patients from the International Study to Predict Optimized Treatment in Depression (iSPOT-D) who completed baseline and 8-week follow-up visits and for whom complete genotyping data were available. The authors tested the relationship between genotype at 16 candidate HPA axis single-nucleotide polymorphisms (SNPs) and treatment outcomes for three commonly used antidepressants (escitalopram, sertraline, and extended-release venlafaxine), using multivariable linear and logistic regression with Bonferroni correction. Response and remission were defined using the Hamilton Depression Rating Scale. Findings were then validated using the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study of outcome predictors in treatment-naive patients with major depression. RESULTS: The authors found that the rs28365143 variant within the corticotropin-releasing hormone binding protein (CRHBP) gene predicted antidepressant outcomes for remission, response, and symptom change. Patients homozygous for the G allele of rs28365143 had greater remission rates, response rates, and symptom reductions. These effects were specific to drug class. Patients homozygous for the G allele responded significantly better to the selective serotonin reuptake inhibitors escitalopram and sertraline than did A allele carriers. In contrast, rs28365143 genotype was not associated with treatment outcomes for the serotonin norepinephrine reuptake inhibitor venlafaxine. When patients were stratified by race, the overall effect of genotype on treatment response remained. In the validation sample, the GG genotype was again associated with favorable antidepressant outcomes, with comparable effect sizes. CONCLUSIONS: These findings suggest that a specific CRHBP SNP, rs28365143, may have a role in predicting which patients will improve with antidepressants and which type of antidepressant may be most effective. The results add to the foundational knowledge needed to advance a precision approach to personalized antidepressant choices.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. O'Connell CP, Goldstein-Piekarski AN, Nemeroff CB, et al. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. Am J Psychiatry. 2017. PMID: 29241359. doi:10.1176/appi.ajp.2017.17020172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。